Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma

Table 5

Univariate and multivariate analyses of predictors of overall survival and progression-free survival after treatment.

Factors	Overall survival				Progression-free survival
	Univariate	Multivariate			Univariate	Multivariate
	value	HR	95% CI	value	value	HR	95% CI	value
Gender (male/female)	0.897				0.509
Age (years)	0.690				0.839
HBsAg (+/−)	0.654				0.543
HCV (+/−)	0.876				0.737
Platelet count (×10^9/L) (≤100/>100)	0.285				0.187
Child–Pugh class (A/B)	0.688				0.527
Total bilirubin level (μmol/L) (≤17.1/>17.1)	0.022				0.109
ALB level (g/L) (≤35/>35)	0.678				0.729
Prothrombin activity (%) (≤100/>100)	0.027				0.067
ALT (IU/L) (≤40/>40)	0.018				0.178
AFP (ng/mL) (≤400/>400)	0.286				0.041
Number of tumors (1/>1)	0.326				0.024
Tumor size (≤3/>3 cm)	0.001	0.683	0.541–0.862	0.001	0.009	0.761	0.613–0.944	0.013
Treatment allocation (TACE-RFA/TACE)	0.003	0.701	0.554–0.888	0.003	<0.001	0.620	0.487–0.789	<0.001
Antiviral treatment for hepatitis B (yes/no)	0.967				0.854

TACE: transarterial chemoembolization; RFA: radiofrequency ablation; HR: hazard ratio; CI: confidence interval; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; ALT: alanine aminotransferase; ALB: albumin; GGT: γ-glutamyl transpeptidase; AFP: alpha fetoprotein.